中文 | English
 
郑文云
发布时间：2025-04-01   访问次数:17146   作者:

郑文云 教授，博士生导师、药物科学系主任

研究生招生专业：

         药学专业：博士生/硕士生

         生物与医药专业：博士生/硕士生

联系方式：

通讯地址：上海市徐汇区 梅陇路130号 318信箱，200237  

实验室(Lab)：实验十八楼627/631,  办公室(O)：431室

Tel：13641936878； E-mail：zwy@ecust.edu.cn


个人简历：

郑文云 博士，教授，博士生导师，华东理工大学  药学院/上海市新药设计重点实验室 研究人员、

药物科学系主任、生物制药学实验室/课题组负责人、上海市优秀青年骨干教师。

2006年毕业于沈阳药科大学获理学博士学位，师从杨胜利院士；

2013-2014年美国明尼苏达大学（University of Minnesota）受教育部留学基金委资助访学。


研究领域\研究方向：

研究领域：生物制药\\药理药效与药剂学；

研究方向：生物技术新药研发、药理、药效评价及靶向转载系统研究。


学术兼职与荣誉奖励：

Biochemistry and Molecular Biology编委；Drug Design, Research and Development编委；Biomedcine & Pharmacotherapy特约审稿人；上海市药学会生化与生物技术药物专业委员会委员、上海生物工程学会、中国生物技术药物学会会员。2007年获上海市优秀青年骨干教师荣誉称号；2016年上海科技发明奖（生物医药）三等奖；2015年第28届上海市优秀科技发明选拔赛（银奖）；2015年第28届上海市优秀科技发明选拔赛（铜奖）；2016年校优秀教育教学成果奖二等奖。


承担科研项目：

承担国家自然科学基金，上海市“科技创新”行动计划项目，教育部博士点基金和上海优秀青年骨干教师科研基金项目等，参与国家重点研发计划、国家“十一五”“新药创制”重大专项、教育部交叉学科与重大项目培育基金项目、上海市科技创新行动计划生物医药领域科技支撑项目20余项。

近年主持的主要科研项目：

  1. 国家自然科学基金：“鲨鱼天然抗体IgNAR超稳定分子机制及其特异性纳米抗体(Nb/PD-L1)筛选鉴定与抗肺癌活性研究”；

  2. 国家自然科学基金：“胞外分泌型人巯基氧化酶1(Es-hQSOX1b)剪接体功能及其生物药学意义探索”；

  3. 上海市“科技创新”行动计划项目：“抗肿瘤重组蛋白TmSm临床前药剂学与药理机制研究”；

  4. 教育部博士点基金项目：“分泌型hQSOX1b在细胞基质形成中的机制研究”。

  5. 企业合作项目4项。


部分代表性论文及专利：

  1. Changping Deng, Jiacheng Ma, Yuping Liu, Xikui Tong, Lei Wang, Jiayi Dong, Ping Shi, Meiyan Wang, Wenyun Zheng*, Xingyuan Ma*. Targeting intracellular cancer proteins with tumor-microenvironment-responsive bispecific nanobody-PROTACs for enhanced therapeutic efficacy. MedComm. 2025 ;6(2): e70068.

  2. Yunhui Fu, Yiwen Zhou, Yiying Chen, Zhedan Zhang, Chen Zhang, Changping Deng, Xikui Tong, Wenyun Zheng*，Meiyan Wang* and Xingyuan M*. Development of ZmT-PEG hydrogels through Michael addition reaction and protein self-assembly for 3D cell culture.Biomaterial Science, 2024, 12, 5803-5811   

  3. Lei Wang, Jiayi Dong, Chenglu Wu, Chengyue Yan, Chong Bi, Chengnan Xu, Yilin Wu, WenyunZheng* and Xingyuan Ma*. Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition.Frontiers in Bioengineering and Biotechnology, 2024,12: 1440150.

  4. Changping Deng, Shihui Li, Yuping Liu, Wen Bao, Chengnan Xu, Wenyun Zheng*, Meiyan Wang, Xingyuan Ma*. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras ontogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clinical and Translational Medicine. 2023, 13(8): e1382.   

  5. Hui Miao, Chang Liu, Hao Ouyang, Peiwen Zhang, Yuping Liu, Chen Zhang, Changping Deng, Yunhui Fu, Jinping Niu, Wenyun Zheng*, Fang You, Yi Yang* and Xingyuan Ma*. A nanobody-based molecular toolkit for ubiquitin-proteasome system explores the main role of survivin subcellular localization. Frontiers in Bioengineering and Biotechnology, 2023, 10.3389  

  6. Fabiao Hu, Changping Deng, Yiwen Zhou, Yuping Liu, Tong Zhang, Peiwen Zhang, Zhangting Zhao, Hui Miao, Wenyun Zheng*, Wenliang Zhang, Meiyan Wang*, Xingyuan Ma*, Multistage targeting and dual inhibiting strategies based on bioengineered tumor matrix microenvironment-mediated protein nanocages for enhancing cancer biotherapy,Bioengineering & Translational Medicine, 2022; 7(2): e10290.

  7. Changping Deng, Fabiao Hu, Zhangting Zhao, Yiwen Zhou, Yuping Liu, Tong Zhang, Shihui Li, Wenyun Zheng*, Wenliang Zhang, Tianwen Wang*, Xingyuan Ma*. The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-glycoprotein in Cancer Multi-drug Resistance, Frontiers in Cell and Developmental Biology, 2021,10.3389.

  8. Wei Guo, Xingyuan Ma, Yunhui Fu, Chang Liu, Qiuli Liu, Fabiao Hu, Hui Miao, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang* and Wenyun Zheng*. Discovering and characterizing of survivin dominant negative mutants with stronger pro-apoptotic activity on cancer cells and CSCs. Frontiers in Oncology. 2021, 11:635233.

  9. Jifan Nie, Xingyuan Ma, Fabiao Hu, Hui Miao, Peiwen Zhang, Myong Hun Han, Fang You, YiYang, WenyunZheng*. Designing and constructing a phage display synthesized single domain antibodies library based on camel VHH frame for  screening and identifying humanized TNF-α-specific nanobody，Biomedicine & Pharmacotherapy, 2021, DOI: 10.1016/j.biopha.2021.111328

  10. Zhangting Zhao, Xingyuan Ma, Ruihuan Zhang, Fabiao Hu, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang⁎, Wenyun Zheng*. A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope 2 self-replication DNA vaccine and its preliminary immune evaluation in 3 experimental animals. Nanomedicine: Nanotechnology, Biology, and Medicine. 2021, (35): 102338.

  11. Lingke Liu, Xiaoxiao Chen, Ruilin Gao, Kejian Wang, Wenyun Zheng∗, Haipeng Liu∗. A cytokine receptor domeless promotes white spot syndrome virus infection via JAK/STAT signaling pathway in red claw crayfish Cherax quadricarinatus. Developmental and Comparative Immunology, 2020, 111: 103749.

  12. Fabiao Hu, Ruihuan Zhang, Wei Guo, Ting Yan, Xiujuan He, Fengzhi Hu, Fuzheng Ren, Xingyuan Ma*, Jiandu Lei, Wenyun Zheng*. PEGylated-PLGA Nanoparticles Coated With pH Responsive Tannic acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer，Molecular Pharmaceutics. 2021, 18(6):2161-2173.

  13. Fabiao Hu,Ting Yan, Wei Guo, Qiuli Liu, Myong Hun Han, Chang Liu,Yuping Liu, Wenyun Zheng*, Fang You*, Yi Yang, Wenliang Zhang and Xingyuan Ma*. Multiple targeting strategies achieve novel protein drug deliver into cancer cells to proapoptosis lung cancer cell by precisely inhibiting surviving. Nanoscale. 2020, 12,10623-10638.

  14. Wenpeng Wang#, Wenyun Zheng#, Fengzhi Hu, Xiujuan He, Dong Wu, Wenliang Zhang, Haipeng Liu，and Xingyuan Ma*. Enhanced Biosynthesis Performance of Heterologous Proteins in CHO-K1 Cells Using CRISPR-Cas9. ACS Synth. Biol. 2018, 7, 1259-1268.

  15. Chen XX, Li YY, Chang XJ, Xie XL, Liang YT, Wang KJ, Zheng WY*, Liu HP*. A CqFerritin protein inhibits white spot syndrome virus infection via regulating iron ions in red claw crayfish Cherax quadricarinatus. Dev Comp Immunol.2018; 82:104-112.  

  16. Fabiao Hu, Daxia Pan, Wenyun Zheng*, Xiujuan He, Fuzheng Ren, Yiming Lu, Xingyuan Ma.Elucidating respective functions of two domains BIR and CHelix of human IAP survivin for precise targeted regulating mitotic cycleapoptosis and autophagy of cancer cells. Oncotarget. 2017,8(69):113687-113700.

  17. Di Liu, Fabiao Hu, Wenpeng Wang, Dong Wu, Xiujuan He, Wenyun Zheng*, Haipeng Liu*, Xingyuan Ma*. Elucidating bottlenecks of the efficient preparation of an AB5hexamer mucosal adjuvant protein LTm by genetic engineering. Journal of Microbiology and Biotechnology. 2017, 27(8):1461-147.

  18. Xingyuan Ma, Yi Zhang, Yanyan Kang, Linfeng Li, Wenyun Zheng*. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells (BCSCs) by down-regulating the expression of Cyclin D1. Biomedicine & Pharmacotherapy, 2016, 23(84):373-381

  19. Xingyuan Ma, Nanjing Lin, Yanyan Kang, Linfeng Li, Wenyun Zheng*, Screening and identification of highly specific McAbs for discovering novel biomarkers of bone marrow stromal cells, Monoclonal Antibody in immunodiagnosis and immunotherapy, 2016, 35(4): 199-211.

  20. Liqun Wang, Yanyan Kang, Wenyun Zheng*, Linfeng Li, Lei Shi, Xingyuan Ma. Effect on apoptosis and cell cycle of recombinant double negative dominant mutation Survivin (T34/117A) in breast cancer cell B-Cap-37. Biomedicine & Pharmacotherapy, 2014, 68(3): 277–284

  21. Nanjing Lin#, Wenyun Zheng#, Linfeng Li, Hui Liu, Tianwen Wang, Ping Wang, Xingyuan Ma*. A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells.Targeted Oncology. 2014, 9(2): 163-170.

  22. Wenyun Zheng, Wenyao Zhang, Wei Hu, and Yi Yang，Exploring the Smallest Active Fragment of HsQSOX1b and Discovery of a Highly Efficient Oxidative Engine,PLoS One. 2012,7 (7): e40935. doi:10.1371.

  23. Yuxin Xu#, Wenyun Zheng#, Tianwen Wang, Ping Wang, Ling Zhu, Xingyuan Ma*. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin. Biomedicine & Pharmacotherapy, 2012, 66(5): 368-372.

  24. Wenyun Zheng, Yanyan Chu, Qin Yin, Charles Yang, Wenyao Zhang, Yun Tang, Yi Yang. Crucial effect of the First CXXC Motif of Human QSOX 1b on the Activity to different substrates. Journal of Biochemistry. 2011, 149(3):293-300.

  25. Wenyun Zheng, Yanyan Kang, Linfeng Li, Yuxin Xu, Xingyuan Ma, Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discoveries & Therapeutics. 2011, 5(6):293-2989.  


授权专利：

1.  发明名称：抗PD-L1纳米抗体及其应用，专利授权号：ZL202010808068.8

2.  发明名称：基于鲨鱼抗体可变区V-NAR的噬菌体文库及其构建方法,专利授权号：ZL202010808119.7

3.  发明名称：靶向TNF-α的人源化纳米抗体及其制备和用途，专利授权号：ZL202011297844.9

4.  发明名称：负载Survivin双抑制剂的铁蛋白纳米颗粒及其制备方法和应用, 专利授权号: ZL202010397566.8

5.  发明名称：抑制WSSV增殖的半胱天冬氨酸酶基因Cq-caspase及其蛋白抗病毒活性应用，专利授权号:  ZL201811089877.7

6.  发明名称：纳米抗体靶向性泛素化降解细胞内源性Survivin组合物及其应用，专利授权号：ZL202010421352.X

7. 发明名称: 一种肿瘤化疗药物的蛋白增敏剂，专利授权号： ZL201010608978.8

8.  发明名称：一种增强多肽药物从细胞内体逃离的蛋白载药系统及其应用；专利授权号：ZL201310178357.4

9. 发明名称：一种内含肽介导的类弹性蛋白纯化重组蛋白的方法，专利授权号：ZL201110236772.1

10. 发明名称：来自LT亚基的细胞穿膜肽LTA2作为细胞内药物运输载体的应用，专利授权号：ZL201410785006.4

11.  发明名称：一种基于组合自剪切与蛋白支架的生物活性小肽制备方法，专利授权号：ZL201611243905.7


诚邀您的访问和加盟:合作共赢！